Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models by Annie De Groot | Aug 2, 2019Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models
Preclinical development of HIvax: human survivin Highly Immunogenic vaccines by epivax3 | Oct 22, 2016
Highly Immunogenic Vaccine For Prevention and Therapy of Malignant Mesothelioma by epivax3 | Oct 21, 2016
